Junevity Partners with Sunrise BioVentures as Advisors to Accelerate siRNA Therapeutic Development
Industry veterans from Sunrise BioVentures to provide strategic and operational support as the company advances its JUN_01 siRNA cardiometabolism program toward Phase 1 clinical trials and progresses its RESET Platform pipeline
Junevity, a biotechnology company on a mission to extend lifespan and healthspan with siRNA therapeutics, today announced a partnership with Sunrise BioVentures (“Sunrise”), a leading RNA therapeutics accelerator. Sunrise leadership comprises RNA veterans Andrew Fraley, Ph.D., Rachel Meyers, Ph.D., Stuart Milstein, Ph.D., and Laurence Reid, Ph.D., who focus on the rapid advancement of novel oligonucleotide therapeutics and platforms. The Sunrise team brings decades of experience spanning the discovery and development of siRNA and other nucleic acid therapeutics at pioneering companies, including Alnylam Pharmaceuticals, Korro Bio, Judo Bio and Decibel Therapeutics.
The Sunrise team will provide active, strategic and operational guidance across Junevity's siRNA development, preclinical validation, pipeline strategy and business development as the company advances its lead candidate, JUN_01, toward Phase 1 clinical trials for cardiovascular risk in type 2 diabetes, anticipated to begin in the fourth quarter of 2026. JUN_01 is the first known siRNA candidate designed to reprogram metabolism to a healthier state, with preclinical studies demonstrating reduced inflammation, reduced cardiovascular risk markers, robust HbA1c reduction and improved insulin sensitivity, with dosing once every six to twelve months.
